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The commonest cause of death from advanced colorectal
cancer is disease progression of hepatic metastases.
Surgical series and cohorts of patients undergoing
thermal ablation have demonstrated that improvement
of local control of liver metastases can improve overall
survival. Selective internal radiation therapy (SIRT),
also known as radioembolisation, is a technique for
administering resin or glass microspheres that contain
yttrium-90 to unresectable primary or secondary hepatic
malignancies via the liver’s arterial supply in a single
procedure.
Clinical trials of SIRT used with concomitant radiosen-
sitising chemotherapy have shown promising results in
patients with metastatic colorectal cancer (Table 1). 1−7
The combination of SIRT and systemic chemotherapy
can downstage a signiﬁcant proportion of patients with
unresectable liver metastases to render them amenable
to potentially curative surgery or ablation.
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Chemoradiation studies suggest that the greatest
clinical beneﬁt to be gained from yttrium-90 microsphere
therapy for metastases is by rational combination with
radiosensitising systemic chemotherapy. 8,9 There is an
established evidence base for rational combination of
SIRT with ﬂuoropyrimidine-, oxaliplatin- and irinotecan-
based regimes, based on radiobiological principles, and
knowledge of DNA damage repair. 1−3 Scheduling of SIRT
has tended to be on days 2−4 of a chemotherapy cycle
(Table 2), 1−3,7,10 which has demonstrated an acceptable
safety proﬁle. In preclinical models, it is known that
levels of DNA damage can peak 24−48h after the end of
exposure of cancer cells to DNA-damaging agents such
as oxaliplatin, 11 which would justify the timing of SIRT if
the treatment intent is to inﬂict maximal levels of DNA
damage on cancer cells. Alternatively, some researchers
have performed SIRT on day 1 of chemotherapy and have
shown it to be safe in the context of radiosensitisation. 7
The evidence base for combining SIRT and chemo-
therapy in the ﬁrst-line treatment of metastatic col-
orectal cancer is robust enough for 2 large-scale
phase III trials, NCRN FOXFIRE and SIRFLOX, to have
been initiated to test the hypothesis that the greatest
clinical beneﬁt from SIRT may be achieved from
this combination therapy at an early time point in
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Table 1 – Selective internal radiation therapy (SIRT) in combination with systemic chemotherapy in unresectable
liver-dominant metastatic colorectal cancer: Summary of published studies
Reference Therapy N ORR SD Median TTP‡ or
PFS (months)
P value Median survival
(months)
P value
First-Line
van Hazel et al. 2004 1 SIRT + FU/LV 11 90.1% 9.9% 18.6‡ <0.0005 29.4 0.025
5-FU/LV 10 0.0% 60.0% 3.6‡ 12.8 1
Sharma et al. 2007 2 SIRT + FOLFOX 20 90.0% 10.0% 9.3 (14.2 liver only) n.r.
Kosmider et al. 2011 3 SIRT + FOLFOX4 or 5-FU 29 84.0% 10.4 29.4 (37.8 liver only)
Tie et al. 2011 4 SIRT + FOLFOX4 or 5-FU 91.0% 13.2
(16.4 liver only)
30.7
Second- or Third-Line
Lim et al. 2005 5 SIRT+ 5-FU/LV 30 33.0% 27.0% 5.3‡ n.r.
Van Hazel et al. 2009 6 SIRT + Irinotecan 25 48.0% 39.0% 6.0 (9.2 liver only) 12.2
Salvage therapy
Hendlisz et al. 2010 7 SIRT+ 5-FU 21 0% 85% 4.5 (5.5 liver only) 0.003 10.0 n.s.
5-FU (with SIRT at
progression in 10 pts)
23 0% 35% 2.1 7.3
ORR: overall response rate; TTP: time to progression; PFS: Progression free survival; n.r.: Not reported; n.s.: Not signiﬁcant.
Table 2 – Radiosensitising chemotherapeutic regimens combined with SIRT for mCRC (Cycle 1 is deﬁned
as the ﬁrst cycle with radioembolisation)
Regimen Schedulea Timing of 90Y resin
microspheres
administration
5-FU protracted IV infusion
Hendlisz et al. 2010 7
Cycle 1: 5-FU infusion (225mg/m2) on days 1−14 every 3 weeks
Cycle 2 onwards: 5-FU infusion (300mg/m2) on days 1−14 every 3 weeks
1st day of the ﬁrst
chemotherapy cycle
with SIRT
Infusional 5-FU/LV
van Hazel et al. 2009 1;
Kosmider et al. 2011 3
Bolus 5-FU (400mg/m2) on day 1, leucovorin (400mg/m2), followed by a
46h infusion of 5-FU (2,400−3,000mg/m2) every 2 weeks
3rd or 4th day of the
chemotherapy cycle
Irinotecan
van Hazel et al. 2009 6
Irinotecan (100mg/m2) on days 1 and 8 every 3 weeks 2nd or 3rd day of the
chemotherapy cycle
OxMdG/FOLFOX4
Sharma et al. 2007 2
Cycles 1−3: Oxaliplatin (60mg/m2) on day 1, bolus 5-FU (400mg/m2), leucovorin
(175mg not adjusted for patient body surface area) followed by a 46h infusion of
5-FU (2,400mg/m2) every 2 weeks
Cycle 4 onwards: OxMdG regimen with oxaliplatin 85mg/m2
3rd or 4th day of the
ﬁrst chemotherapy
cycle with SIRT
FOLFOX6m
Kosmider et al. 2011 3
Cycles 1−3: Oxaliplatin (60mg/m2); bolus 5-FU (400mg/m2), leucovorin, (200mg/m2)
followed by a 46h infusion of 5-FU (2,400mg/m2) every 2 weeks
Cycle 4 onwards: FOLFOX6m regimen with oxaliplatin 85mg/m2
3rd or 4th day of the
ﬁrst chemotherapy
cycle with SIRT
Capecitabine
Currently in a clinical trial:
Cohen et al. 2011 10
Capecitabine (900mg/m2) on days 1−14 every 3 weeks
Capecitabine (1000mg/m2) is currently under clinical investigation
2nd day of the
chemotherapy cycle
Bevacuzimab Patients who have received bevacizumab are advised to stop the drug 6−8 weeks
prior to SIRT
Under investigation:
http://clinicaltrials.gov/
ct2/show/NCT00724503
Cetuximab Patients who have received cetuximab are advised to stop the drug 4−6 weeks prior
to SIRT
Under investigation:
http://clinicaltrials.gov/
ct2/show/NCT00766220
5-FU: 5-ﬂuorouracil; LV: leucovorin; OxMdG: Oxaliplatin + modiﬁed de Gramont regimen of 5-FU/LV.
a Boldface text shows modiﬁcation.
a patient’s disease course. These randomised trials
should provide high-quality evidence regarding whether
this strategy improves the overall survival of patients
with liver-dominant or liver-only unresectable liver
metastases, and which subgroups of patients beneﬁt
most. They will also provide data on quality of life,
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health economics, liver-speciﬁc progression-free survival
relative to progression-free survival and resection rates
post-SIRT.
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